Welcome to our dedicated page for Nano-X Imaging Ltd. news (Ticker: NNOX), a resource for investors and traders seeking the latest updates and insights on Nano-X Imaging Ltd. stock.
NANO-X IMAGING LTD (Nanox) (NASDAQ: NNOX) is a medical imaging technology company that combines imaging hardware, AI-based software, cloud infrastructure, and teleradiology services. The Nanox news feed on this page aggregates company press releases and market updates so readers can follow how Nanox advances its imaging platform, commercial strategy, and capital markets activity over time.
Nanox’s recent news highlights its Nanox.ARC and Nanox.ARC X multi-source digital tomosynthesis systems, including CE Mark certification for Nanox.ARC in Europe and FDA 510(k) clearance for Nanox.ARC X for general use in multiple clinical indications. Articles also cover distribution agreements and collaborations with partners in countries such as France, the Czech Republic, Greece, Romania, Serbia, Montenegro, and Bosnia and Herzegovina, reflecting efforts to expand clinical and commercial deployment of its imaging solutions.
Another key news theme is the growth of Nanox.AI and its imaging analytics portfolio. Press releases describe AI algorithms that analyze routine CT scans for early signs associated with chronic diseases and bone health solutions such as HealthVCF and HealthOST, which have been included in an Early Value Assessment by the UK National Institute for Health and Care Excellence. Updates also discuss acquisitions like VasoHealthcare IT, intended to support deployment of AI solutions across U.S. healthcare facilities.
Investors and analysts can also find financial results announcements, guidance updates, and details of registered direct offerings and other financings, as reported in Nanox’s press releases and related SEC filings. Together, these news items provide insight into Nanox’s commercialization progress, clinical collaborations, AI development roadmap, and capital strategy. Bookmark this page to access an organized stream of Nanox news, from product and partnership updates to financial and regulatory disclosures.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced its Q3 2022 results, reporting $2.4 million in revenue, up from $2.2 million in Q2 2022. The company reported a net loss of $19.1 million, compared to $13.5 million in Q3 2021, largely due to increased R&D and administrative expenses.
As of September 30, 2022, NNOX held $117.1 million in cash and marketable securities, reflecting a decrease of $39.5 million in cash flow from operations over the nine-month period. The company is advancing its Nanox.ARC imaging system and has received a Helsinki permit for clinical trials.
Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its Q3 financial results on November 10, 2022. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET to discuss the results and provide a business update. The call can be accessed via a registration link and will also be available as a live webcast. The company focuses on making diagnostic imaging more accessible globally with its proprietary technology, including the Nanox.ARC and Nanox.CLOUD, aiming to enhance early medical condition detection and improve health outcomes.
Nanox Imaging Ltd (Nasdaq: NNOX) will host its first in-person ARC Day from November 15-17, 2022, at its headquarters in Neve Ilan, Israel. The event aims to showcase the Nanox.ARC imaging system and its integrated AI technology and teleradiology services. A live demonstration will occur on November 16 at 9:30 AM ET, followed by a Q&A session. The company aims to enhance global access to medical imaging, targeting regions lacking sufficient medical imaging capabilities, thus improving early detection and health outcomes.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced participation in two investor conferences in September 2022. The management team, including CEO Erez Meltzer and CFO Ran Daniel, will present at the LifeSci Partners HealthTech Symposium on September 21 at 8:30 AM ET and the Ladenburg Thalmann Healthcare Conference on September 29 at 4:30 PM ET. Both presentations will be streamed live, with replays available on the Company’s website. Nanox aims to enhance accessibility to diagnostic imaging through innovative technology, thereby improving health outcomes globally.
Nano-X Imaging Ltd (NASDAQ: NNOX) reported a revenue increase to $2.2 million for Q2 2022, up from $1.8 million in Q1 2022. Cash, cash equivalents, and marketable securities totaled $126.7 million as of June 30, 2022. Key developments include plans for deploying the Nanox.ARC in Nigeria and a partnership with BIO Ventures for Global Health. The company faced a net loss of $19.6 million, compared to $13.6 million in Q2 2021, largely due to increased R&D and general administrative expenses. The gross loss was $1.8 million during the quarter.
Nano-X Imaging Ltd (NASDAQ: NNOX) will announce its Q2 financial results ending June 30, 2022, on August 16, 2022, before market opening. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET for a business update. The company aims to enhance accessibility to medical imaging through its technology, which includes the Nanox System and Nanox.CLOUD. Forward-looking statements carry risks related to technology development and market acceptance, underscoring the uncertainties surrounding the company's future performance.
NANO-X IMAGING LTD (NASDAQ: NNOX) reported its first-quarter 2022 results, achieving $1.8 million in revenue, a notable increase from $0 in Q1 2021. This reflects a 38% growth compared to $1.3 million in Q4 2021. The company reported a net loss of $21.7 million, up from $12.7 million in the prior year, driven by increased R&D and administrative expenses. As of March 31, 2022, cash and marketable securities stood at $139.5 million. The company continues to make strides in securing regulatory approvals and expanding its customer base.
Nano-X Imaging Ltd (NASDAQ: NNOX) will release its Q1 2022 results on May 19, 2022, before market opening. CEO Erez Meltzer and CFO Ran Daniel will host a conference call at 8:30 a.m. ET to discuss the results and business updates. Interested parties can join via phone or access the webcast through provided links. Nano-X is committed to enhancing diagnostic imaging accessibility and affordability globally, utilizing advanced technology like the Nanox.ARC and Nanox.CLOUD.
NANO-X IMAGING LTD (Nasdaq: NNOX) has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021, with the U.S. SEC on May 2, 2022. This report includes the company's audited consolidated financial statements, which can be accessed on the SEC's and Nanox's websites. Nanox aims to enhance diagnostic medicine accessibility and affordability through its proprietary imaging technology and solutions. Shareholders can request a hard copy of the annual report free of charge by contacting Investor Relations.
NANO-X IMAGING LTD (NASDAQ: NNOX) announced FDA 510(k) clearance for its HealthOST device, an AI software for detailed spinal analysis, particularly in diagnosing vertebral compression fractures and low bone density. This is the tenth FDA clearance for Nanox.AI, enhancing its portfolio aimed at improving musculoskeletal disease detection. HealthOST aims to support clinicians and potentially prevent serious conditions like osteoporosis, affecting over 10 million in the U.S. The device offers precise measurements and automated identification of critical findings.